{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:17:04Z","timestamp":1790266624376,"version":"4.1.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.bmc.2017.04.031","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T21:46:40Z","timestamp":1493329600000},"page":"3259-3277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine"],"prefix":"10.1016","volume":"25","author":[{"given":"Vin\u00edcius Barros Ribeiro","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Rafaella Koresch Leiva","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamerson Ferreira","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Decout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8277-3458","authenticated-orcid":false,"given":"Maria","family":"do Carmo Alves de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2017.04.031_b0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0065-308X(05)62007-6","article-title":"Global epidemiology, ecology and control of soil-transmitted helminth infections","volume":"62","author":"Brooker","year":"2006","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(06)69440-3","article-title":"Human schistosomiasis","volume":"368","author":"Gryseels","year":"2006","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bmc.2017.04.031_b0015","unstructured":"WHO IRIS: Schistosomiasis: progress report 2001\u20132011, strategic plan 2012\u20132020. WHO (2013). Available at: http:\/\/apps.who.int\/iris\/handle\/10665\/78074. (Accessed: 17th October 2016)."},{"key":"10.1016\/j.bmc.2017.04.031_b0020","unstructured":"WHO|First WHO report on neglected tropical diseases. WHO (2010). Available at: http:\/\/www.who.int\/neglected_diseases\/2010report\/en\/. (Accessed: 17th October 2016)."},{"key":"10.1016\/j.bmc.2017.04.031_b0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"Steinmann","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1471-4922(02)02301-2","article-title":"Schistosomiasis: from risk assessment to control","volume":"18","author":"Bergquist","year":"2006","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri843","article-title":"The immunobiology of schistosomiasis","volume":"2","author":"Pearce","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmc.2017.04.031_b0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00436-001-0587-y","article-title":"Chemotherapeutic approaches to schistosomes: current knowledge and outlook","volume":"88","author":"Harder","year":"2002","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0045","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1371\/journal.pmed.0030102","article-title":"Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV\/AIDS, tuberculosis, and malaria","volume":"3","author":"Hotez","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.bmc.2017.04.031_b0050","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1371\/journal.pntd.0000485","article-title":"Schistosomiasis in Africa: an emerging tragedy in our new global health decade","volume":"3","author":"Hotez","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1590\/S0074-02762010000400040","article-title":"Specific schistosomiasis treatment as a strategy for disease control","volume":"105","author":"Coura","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmc.2017.04.031_b0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0140-6736(01)02807-0","article-title":"The successful use of antimony in bilharziosis","volume":"192","author":"Christopherson","year":"1918","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2017.04.031_b0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1476-5381.1957.tb00114.x","article-title":"The relationship between inhibition of phosphofructokinase activity and the mode of action of trivalent organic antimonials on Schistosoma mansoni","volume":"12","author":"Bueding","year":"1957","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.bmc.2017.04.031_b0070","series-title":"Small Animal Clinical Pharmacology","author":"Maddison","year":"2008"},{"key":"10.1016\/j.bmc.2017.04.031_b0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0773.1981.tb03248.x","article-title":"Chemistry of metrifonate and dichlorvos","volume":"49","author":"Hofer","year":"1981","journal-title":"Acta Pharmacol Toxicol (Copenh.)"},{"key":"10.1016\/j.bmc.2017.04.031_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0163-7258(95)00026-7","article-title":"Antischistosomal drugs: past, present Ellipsis and future?","volume":"68","author":"Cioli","year":"1995","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2017.04.031_b0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4269\/ajtmh.1977.26.234","article-title":"Field trials with oxamniquine in a Schistosomiasis mansoni-endemic area","volume":"26","author":"Katz","year":"1977","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0090","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1590\/S0100-40422009000900038","article-title":"Chemotherapy of Chagas\u2019 disease: state of the art and perspectives for the development of new drugs","volume":"32","author":"Dias","year":"2009","journal-title":"Quim Nova"},{"key":"10.1016\/j.bmc.2017.04.031_b0095","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1897\/02-220","article-title":"Mutagenicity of nitroaromatic degradation compounds","volume":"22","author":"Padda","year":"2003","journal-title":"Environ Toxicol Chem SETAC"},{"key":"10.1016\/j.bmc.2017.04.031_b0100","doi-asserted-by":"crossref","unstructured":"Rieger PG, Knackmuss HJ. Biodegradation of Nitroaromatic Compounds (ed. Spain, J. C.) 1\u201318 (Springer, US, 1995). doi:10.1007\/978-1-4757-9447-2_1.","DOI":"10.1007\/978-1-4757-9447-2_1"},{"key":"10.1016\/j.bmc.2017.04.031_b0105","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/tx000002x","article-title":"Mutagenicity of nitroaromatic compounds","volume":"13","author":"Purohit","year":"2000","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2017.04.031_b0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1128\/MMBR.00006-10","article-title":"Nitroaromatic compounds, from synthesis to biodegradation","volume":"74","author":"Ju","year":"2010","journal-title":"Microbiol Mol Biol Rev MMBR"},{"key":"10.1016\/j.bmc.2017.04.031_b0115","doi-asserted-by":"crossref","unstructured":"Archer S, Yarinsky A. Recent developments in the chemotherapy of schistosomiasis. Prog. Drug Res. Fortschritte Arzneimittelforschung Progres Rech. Pharm. 1972;16:11\u201366.","DOI":"10.1007\/978-3-0348-7081-8_1"},{"key":"10.1016\/j.bmc.2017.04.031_b0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4269\/ajtmh.1967.16.487","article-title":"Comparison of oral and parenteral activity of hycanthone and lucanthone in experimental infections with Schistosoma mansoni","volume":"16","author":"Berberian","year":"1967","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/15287397509529329","article-title":"Results of tests for possible transmitted genetic effects of hycanthone in mammals","volume":"1","author":"Russell","year":"1975","journal-title":"J Toxicol Environ Health"},{"key":"10.1016\/j.bmc.2017.04.031_b0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijc.2910230117","article-title":"Carcinogenic potential of hycanthone in mice and hamsters","volume":"23","author":"Bulay","year":"1979","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmc.2017.04.031_b0135","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0360-3016(97)00113-2","article-title":"Topoisomerase inhibition by lucanthone, an adjuvant in radiation therapy","volume":"37","author":"Bases","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bmc.2017.04.031_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0360-3016(98)00374-5","article-title":"Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone","volume":"43","author":"Del Rowe","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bmc.2017.04.031_b0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.1980.29.426","article-title":"Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with bilarcil","volume":"29","author":"Nordgren","year":"1980","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0150","unstructured":"WHO. WHO Model List of Essential Medicines. (2015). Available at: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML_2015_FINAL_amended_NOV2015.pdf?ua=1. (Accessed: 6th October 2016)."},{"key":"10.1016\/j.bmc.2017.04.031_b0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1590\/S0100-40421999000100002","article-title":"S\u00edntese do anti-helm\u00edntico praziquantel, a partir da glicina","volume":"22","author":"Novaes","year":"1999","journal-title":"Qu\u00edm Nova"},{"key":"10.1016\/j.bmc.2017.04.031_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0169-4758(89)90008-2","article-title":"Reinfection after treatment of schistosome infections","volume":"5","author":"Wilkins","year":"1989","journal-title":"Parasitol Today"},{"key":"10.1016\/j.bmc.2017.04.031_b0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1590\/S0036-46651997000200006","article-title":"Evaluation of the schistosomicidal efficacy of liposome \u2013 entrapped oxamniquine","volume":"39","author":"Fr\u00e9zard","year":"1997","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0170","first-page":"98","article-title":"Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice","volume":"97","author":"Giboda","year":"1994","journal-title":"J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0169-4758(98)01323-4","article-title":"Chemotherapy of schistosomiasis: an update","volume":"14","author":"Cioli","year":"1998","journal-title":"Parasitol Today"},{"key":"10.1016\/j.bmc.2017.04.031_b0180","first-page":"209","article-title":"Efeito do praziquantel incorporado a lipossomas nos diferentes est\u00e1gios de desenvolvimento dos ovos de Schistosoma mansoni","volume":"28","author":"Frezza","year":"2007","journal-title":"Rev Cienc Farm Basica E Apl"},{"key":"10.1016\/j.bmc.2017.04.031_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8510(98)00002-5","article-title":"Dilemmas in drug development for tropical diseases. Experiences with praziquantel","volume":"44","author":"Reich","year":"1998","journal-title":"Health Policy"},{"key":"10.1016\/j.bmc.2017.04.031_b0190","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jocn.2008.10.030","article-title":"Neurocysticercosis: a review of current status and management","volume":"16","author":"Sinha","year":"2009","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.bmc.2017.04.031_b0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.jepm.2009.06.005","article-title":"Praziquantel","volume":"18","author":"Watson","year":"2009","journal-title":"J Exot Pet Med"},{"key":"10.1016\/j.bmc.2017.04.031_b0200","doi-asserted-by":"crossref","first-page":"290","DOI":"10.7326\/0003-4819-110-4-290","article-title":"Drugs five years later: praziquantel","volume":"110","author":"King","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmc.2017.04.031_b0205","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4155\/fmc.15.11","article-title":"What is the mechanism of action of praziquantel and how might resistance strike?","volume":"7","author":"Cupit","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejmech.2014.07.007","article-title":"New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni","volume":"84","author":"Guglielmo","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","article-title":"Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis","volume":"21","author":"Doenhoff","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpara.2004.09.004","article-title":"Are Ca2+ channels targets of praziquantel action?","volume":"35","author":"Greenberg","year":"2005","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0225","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2471\/BLT.08.058669","article-title":"Global trends in schistosomiasis control","volume":"86","author":"Taylor","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bmc.2017.04.031_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001260","article-title":"Resolution of praziquantel","volume":"5","author":"Woelfle","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2006.03.028","article-title":"Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel","volume":"318","author":"Passerini","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmc.2017.04.031_b0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/snep.2003.50003","article-title":"Schistosomiasis and the kidney","volume":"23","author":"Barsoum","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.bmc.2017.04.031_b0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.01.033","article-title":"In vitro characterization of some biopharmaceutical properties of praziquantel","volume":"295","author":"Gonz\u00e1lez-Esquivel","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmc.2017.04.031_b0250","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00436-002-0751-z","article-title":"Praziquantel","volume":"90","author":"Cioli","year":"2003","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1043-6618(02)00251-7","article-title":"Effects of liquid and freeze-dried grapefruit juice on the pharmacokinetics of praziquantel and its metabolite 4\u2019-hydroxy praziquantel in beagle dogs","volume":"47","author":"Giorgi","year":"2003","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0260","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/AAC.44.10.2903-2904.2000","article-title":"Bioavailability of praziquantel increases with concomitant administration of food","volume":"44","author":"Castro","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2017.04.031_b0265","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0035-9203(90)90333-A","article-title":"Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis","volume":"84","author":"Mandour","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-99-2-195","article-title":"Praziquantel: a major advance in anthelminthic therapy","volume":"99","author":"Pearson","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmc.2017.04.031_b0275","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00560463","article-title":"Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics","volume":"14","author":"Leopold","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2017.04.031_b0280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics","volume":"86","author":"Dayan","year":"2003","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2017.04.031_b0285","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.bmcl.2007.05.063","article-title":"Praziquantel derivatives I: modification of the aromatic ring","volume":"17","author":"Ronketti","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.04.031_b0290","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0006-2952(94)90464-2","article-title":"Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors","volume":"48","author":"Masimirembwa","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2017.04.031_b0295","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/314686","article-title":"Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths","volume":"179","author":"Olds","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0300","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.41.6.1256","article-title":"Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen","volume":"41","author":"Jung","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2017.04.031_b0305","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/00003088-199834060-00006","article-title":"Pharmacokinetic optimisation of the treatment of neurocysticercosis","volume":"34","author":"Sotelo","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2017.04.031_b0310","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1016\/j.jchromb.2009.07.036","article-title":"Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS\/MS: Application to pharmacokinetics","volume":"877","author":"Lima","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.bmc.2017.04.031_b0315","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/med.2610030204","article-title":"Praziquantel","volume":"3","author":"Andrews","year":"1983","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2017.04.031_b0320","doi-asserted-by":"crossref","first-page":"809","DOI":"10.4269\/ajtmh.1994.51.809","article-title":"Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure","volume":"51","author":"Guiniady","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0325","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00507974","article-title":"A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum","volume":"304","author":"Pax","year":"1978","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bmc.2017.04.031_b0330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00436-009-1656-x","article-title":"The in vitro effect of mefloquine and praziquantel against juvenile and adult Schistosoma japonicum","volume":"106","author":"Xiao","year":"2009","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6793-8-6","article-title":"Atypical properties of a conventional calcium channel beta subunit from the platyhelminth Schistosoma mansoni","volume":"8","author":"Salvador-Recatal\u00e0","year":"2008","journal-title":"BMC Physiol"},{"key":"10.1016\/j.bmc.2017.04.031_b0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/wmts.19","article-title":"Calcium channels of schistosomes: unresolved questions and unexpected answers","volume":"1","author":"Salvador-Recatal\u00e0","year":"2012","journal-title":"Wiley Interdiscip Rev Membr Transp Signal"},{"key":"10.1016\/j.bmc.2017.04.031_b0345","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.cellbio.16.1.521","article-title":"Structure and regulation of voltage-gated Ca2+ channels","volume":"16","author":"Catterall","year":"2000","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.bmc.2017.04.031_b0350","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/S0031182001008691","article-title":"Structure of three high voltage-activated calcium channel \u03b11 subunits from Schistosoma mansoni","volume":"123","author":"Kohn","year":"2001","journal-title":"Parasitology"},{"key":"10.1016\/j.bmc.2017.04.031_b0355","doi-asserted-by":"crossref","first-page":"36873","DOI":"10.1074\/jbc.C100273200","article-title":"Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel","volume":"276","author":"Kohn","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0360","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S003118200300386X","article-title":"Specific residues in the beta interaction domain of a schistosome Ca2+ channel b subunit are key to its role in sensitivity to the antischistosomal drug praziquantel","volume":"127","author":"Kohn","year":"2003","journal-title":"Parasitology"},{"key":"10.1016\/j.bmc.2017.04.031_b0365","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF00932019","article-title":"Time course of the effect of praziquantel on Schistosoma mansoni attachment in vitro: comparison with its effects on worm length and motility","volume":"81","author":"da Silva","year":"1995","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004086","article-title":"Synergy of omeprazole and praziquantel in vitro treatment against Schistosoma mansoni adult worms","volume":"9","author":"Almeida","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0375","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1126\/science.2511631","article-title":"New weapon in the war against schistosomiasis","volume":"246","author":"Cherfas","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.bmc.2017.04.031_b0380","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijpara.2003.12.003","article-title":"Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment","volume":"34","author":"Pica-Mattoccia","year":"2004","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0385","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.exppara.2005.12.001","article-title":"Schistosoma mekongi: the in vitro effect of praziquantel and artesunate on the adult fluke","volume":"113","author":"Jiraungkoorskul","year":"2006","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0390","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1039\/c3ob41348a","article-title":"Synthesis of fluorescent derivatives of praziquantel: cell-imaging and interaction with Schistosoma japonicum cercariae","volume":"11","author":"Xie","year":"2013","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0395","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.actatropica.2008.05.006","article-title":"Clinical therapy of schistosomiasis mansoni: the Brazilian contribution","volume":"108","author":"Katz","year":"2008","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2017.04.031_b0400","first-page":"781","article-title":"Preliminary trials with praziquantel in human infections due to Schistosoma mansoni","volume":"57","author":"Katz","year":"1979","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bmc.2017.04.031_b0405","first-page":"767","article-title":"Multicentre trials of praziquantel in human schistosomiasis: design and techniques","volume":"57","author":"Davis","year":"1979","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bmc.2017.04.031_b0410","first-page":"787","article-title":"Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections","volume":"57","author":"Ishizaki","year":"1979","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bmc.2017.04.031_b0415","first-page":"793","article-title":"Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines","volume":"57","author":"Santos","year":"1979","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bmc.2017.04.031_b0420","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/0035-9203(84)90007-5","article-title":"Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire","volume":"78","author":"Polderman","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0425","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4269\/ajtmh.1995.53.167","article-title":"Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni","volume":"53","author":"Stelma","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0430","first-page":"201","article-title":"The toxicological profile of praziquantel in comparison to other anthelminthic drugs","volume":"57","author":"Frohberg","year":"1989","journal-title":"Acta Leiden"},{"key":"10.1016\/j.bmc.2017.04.031_b0435","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0165-1110(91)90019-R","volume":"257","author":"Kramers","year":"1991","journal-title":"Mutat Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0440","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.172.3987.1057","article-title":"Hycanthone resistance: development in Schistosoma mansoni","volume":"172","author":"Rogers","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.bmc.2017.04.031_b0445","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1368-7646(98)80004-6","article-title":"Schistosome resistance to praziquantel","volume":"1","author":"Fallon","year":"1998","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmc.2017.04.031_b0450","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0169-4758(96)10029-6","article-title":"Schistosome resistance to praziquantel: fact or artifact?","volume":"12","author":"Fallon","year":"1996","journal-title":"Parasitol Today"},{"key":"10.1016\/j.bmc.2017.04.031_b0455","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/517273","article-title":"Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low","volume":"176","author":"Stelma","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000504","article-title":"Reduced susceptibility to praziquantel among naturally occurring kenyan isolates of Schistosoma mansoni","volume":"3","author":"Melman","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0465","first-page":"128","article-title":"Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel","volume":"24","author":"Kasinathan","year":"2010","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.bmc.2017.04.031_b0470","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molbiopara.2012.09.006","article-title":"Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro","volume":"186","author":"Hines-Kay","year":"2012","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0475","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","article-title":"Susceptibility or resistance of praziquantel in human schistosomiasis: a review","volume":"111","author":"Wang","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0480","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1017\/S003118201000065X","article-title":"Use of fluorescent probes as a useful tool to identify resistant Schistosoma mansoni isolates to praziquantel","volume":"137","author":"Couto","year":"2010","journal-title":"Parasitology"},{"key":"10.1016\/j.bmc.2017.04.031_b0485","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4269\/ajtmh.1991.45.345","article-title":"Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica","volume":"45","author":"Wu","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0490","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00436-009-1371-7","article-title":"Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges","volume":"104","author":"Abdul-Ghani","year":"2009","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0495","unstructured":"WHO | Drug development and evaluation for helminths and other neglected tropical diseases: Business Plan 2008-2013. WHO. Available at: http:\/\/www.who.int\/tdr\/publications\/about-tdr\/business-plans\/bl6-business-plan-2008-2013\/en\/. Accessed October 7, 2016."},{"key":"10.1016\/j.bmc.2017.04.031_b0500","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1371\/journal.pntd.0000357","article-title":"Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment","volume":"3","author":"Meyer","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0505","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bmcl.2011.12.133","article-title":"Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum","volume":"22","author":"Duan","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.04.031_b0510","unstructured":"Seubert J, Thomas H, Andrews P, Haftung MPGMB. 2-acyl-4-oxo-pyrazino-isoquinoline derivatives and process for the preparation thereof., 1977. Available at: https:\/\/www.google.com\/patents\/US4001411. Accessed October 7, 2016."},{"key":"10.1016\/j.bmc.2017.04.031_b0515","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/BF01945954","article-title":"Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes","volume":"33","author":"Seubert","year":"1977","journal-title":"Experientia"},{"key":"10.1016\/j.bmc.2017.04.031_b0520","first-page":"207","article-title":"Synthesis and antischistosomal activity of a new 2-nicotinoyl dipeptide analogue of praziquantel","volume":"46","author":"Abo-Ghalia","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bmc.2017.04.031_b0525","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0020-7519(00)00108-9","article-title":"A direct competitive enzyme-linked immunosorbent assay (ELISA) for determination of praziquantel concentration in serum","volume":"31","author":"Mitsui","year":"2001","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0530","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.bmcl.2010.03.001","article-title":"Praziquantel analogs with activity against juvenile Schistosoma mansoni","volume":"20","author":"Dong","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.04.031_b0535","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1128\/AAC.01537-06","article-title":"In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species","volume":"51","author":"Xiao","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2017.04.031_b0540","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejoc.200700975","article-title":"Synthesis of \u201cTrioxaquantel\u201d\u00ae derivatives as potential new antischistosomal drugs","volume":"5","author":"Laurent","year":"2008","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0545","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0020-7519(02)00108-X","article-title":"Molecular and enzymatic characterisation of Schistosoma mansoni thioredoxin","volume":"32","author":"Alger","year":"2002","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0550","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.bmcl.2011.11.108","article-title":"Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis","volume":"22","author":"Sadhu","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.04.031_b0555","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/cmdc.201000202","article-title":"Praziquantel and schistosomiasis","volume":"5","author":"D\u00f6mling","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2017.04.031_b0560","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1747-0285.2011.01288.x","article-title":"MCR synthesis of praziquantel derivatives","volume":"79","author":"Liu","year":"2012","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2017.04.031_b0565","series-title":"Synthesis of Heterocycles via Multicomponent Reactions I","author":"Orru","year":"2010"},{"key":"10.1016\/j.bmc.2017.04.031_b0570","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1039\/B707077M","article-title":"Bioorganometallic chemistry-from teaching paradigms to medicinal applications","volume":"38","author":"Hartinger","year":"2009","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2017.04.031_b0575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic anticancer compounds","volume":"54","author":"Gasser","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0580","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.1021\/jm301077m","article-title":"Ferrocenyl derivatives of the anthelmintic praziquantel: design, synthesis, and biological evaluation","volume":"55","author":"Patra","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0585","first-page":"2232","article-title":"[(\u03b7(6)-Praziquantel)Cr(CO)3] derivatives with remarkable in vitro anti-schistosomal activity","volume":"19","author":"Patra","year":"2013","journal-title":"Chem Weinh Bergstr Ger"},{"key":"10.1016\/j.bmc.2017.04.031_b0590","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1021\/jm401287m","article-title":"In vitro metabolic profile and in vivo antischistosomal activity studies of (\u03b7(6)-praziquantel)Cr(CO)3 derivatives","volume":"56","author":"Patra","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0595","doi-asserted-by":"crossref","first-page":"9163","DOI":"10.3390\/molecules18089163","article-title":"Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum","volume":"18","author":"Wang","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2017.04.031_b0600","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cbdd.12153","article-title":"Praziquantel derivatives with antischistosomal activity: aromatic ring modification","volume":"82","author":"Wang","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2017.04.031_b0605","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.bmcl.2014.07.039","article-title":"Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum","volume":"24","author":"Zheng","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.04.031_b0610","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1021\/ar100070k","article-title":"Heme as trigger and target for trioxane-containing antimalarial drugs","volume":"43","author":"Meunier","year":"2010","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2017.04.031_b0615","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0020-7519(01)00297-1","article-title":"The potential of artemether for the control of schistosomiasis","volume":"31","author":"Utzinger","year":"2001","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0620","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1371\/journal.pntd.0001474","article-title":"Antischistosomal activity of trioxaquines. In vivo efficacy and mechanism of action on Schistosoma mansoni","volume":"6","author":"Portela","year":"2012","journal-title":"PLOS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0625","first-page":"50","article-title":"Observation on effect of praziquantel combined with artemether on mouse schistosomiasis","volume":"7","author":"You","year":"1994","journal-title":"Chin J Parasit Dis Control"},{"key":"10.1016\/j.bmc.2017.04.031_b0630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1383-5769(00)00029-5","article-title":"Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits","volume":"49","author":"Shuhua","year":"2000","journal-title":"Parasitol Int"},{"key":"10.1016\/j.bmc.2017.04.031_b0635","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/AAC.47.5.1487-1495.2003","article-title":"Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials","volume":"47","author":"Utzinger","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2017.04.031_b0640","doi-asserted-by":"crossref","first-page":"e112163","DOI":"10.1371\/journal.pone.0112163","article-title":"An artemisinin derivative of praziquantel as an orally active antischistosomal agent","volume":"9","author":"Dong","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2017.04.031_b0645","unstructured":"Farmacop\u00e9ia dos Estados Unidos do Brasil. 4th ed. S\u00e3o Paulo: Atheneu, 1988."},{"key":"10.1016\/j.bmc.2017.04.031_b0650","unstructured":"MERCK index. 12th ed. Rahway: Merck & CO., INC., 1995."},{"key":"10.1016\/j.bmc.2017.04.031_b0655","series-title":"Essentials of Medicinal Chemistry","author":"Korolkovas","year":"1988"},{"key":"10.1016\/j.bmc.2017.04.031_b0660","series-title":"Dicion\u00e1rio terap\u00eautico Guanabara","author":"Korolkovas","year":"1999"},{"key":"10.1016\/j.bmc.2017.04.031_b0665","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/BF00763776","article-title":"Advances in the development of new anthelminthics","volume":"20","author":"Tzisin","year":"1986","journal-title":"Pharm Chem J Engl Trans"},{"key":"10.1016\/j.bmc.2017.04.031_b0670","unstructured":"DEF. Dicion\u00e1rio de especialidades farmac\u00eauticas. 44th ed. Rio de Janeiro: EPUB, 2016."},{"key":"10.1016\/j.bmc.2017.04.031_b0675","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0035-9203(87)90282-3","article-title":"A review of clinical experience with oxamniquine","volume":"81","author":"Foster","year":"1987","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0680","first-page":"359","article-title":"Oxamniquine pharmacokinetics in healthy Kenyan African volunteers","volume":"68","author":"Kokwaro","year":"1991","journal-title":"East Afr Med J"},{"key":"10.1016\/j.bmc.2017.04.031_b0685","series-title":"Foye\u2019s Principles of Medicinal Chemistry","author":"Lemke","year":"2012"},{"key":"10.1016\/j.bmc.2017.04.031_b0690","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/19.1.87","article-title":"Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan","volume":"19","author":"Daneshmend","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2017.04.031_b0695","first-page":"41","article-title":"Clinical experiences with, and pharmacokinetics of, oxamniquine","volume":"10","author":"Kaye","year":"1978","journal-title":"Adv Pharmacol Ther"},{"key":"10.1016\/j.bmc.2017.04.031_b0700","unstructured":"WHO. WHO Drug Information. Gen\u00e8ve: WHO, 1989."},{"key":"10.1016\/j.bmc.2017.04.031_b0705","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00003495-199142030-00004","article-title":"Schistosomiasis drug therapy and treatment considerations","volume":"42","author":"Shekhar","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2017.04.031_b0710","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-5173(01)00917-6","article-title":"Synthesis and evaluation of new oxamniquine derivatives","volume":"233","author":"Filho","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmc.2017.04.031_b0715","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1126\/science.1243106","article-title":"Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites","volume":"342","author":"Valentim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bmc.2017.04.031_b0720","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1590\/S0074-02762006000900048","article-title":"The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase","volume":"101","author":"Pica-Mattoccia","year":"2006","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmc.2017.04.031_b0725","series-title":"An Introduction to Medicinal Chemistry","author":"Graham","year":"2013"},{"key":"10.1016\/j.bmc.2017.04.031_b0730","first-page":"103","article-title":"Clinical trials with oral oxamniquine (UK 4271) for the treatment of mansoni schistosomiasis","volume":"16","author":"Silva","year":"1974","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0735","first-page":"164","article-title":"Tratamento da esquistossomose mans\u00f4nica com oxaminquine oral","volume":"17","author":"Domingues","year":"1975","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0740","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1590\/S0037-86821976000400006","article-title":"Convuls\u00e3o associada ao uso de Oxamniquine: relato de um caso","volume":"10","author":"Bina","year":"1976","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.bmc.2017.04.031_b0745","first-page":"371","article-title":"Clinical trials with oxamniquine, by oral route, in schistosomiasis mansoni","volume":"18","author":"Katz","year":"1976","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0750","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4269\/ajtmh.1983.32.1344","article-title":"Safety and toxicity of oxamni quina in the treatment of Schistosoma mansoni infections, with particular reference to electroencephalographic abnormalities","volume":"32","author":"Krajden","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0755","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1590\/S0036-46651985000300004","article-title":"Neurotoxicidade do oxamniquina no tratamento da infec\u00e7\u00e3o humana pelo Schistosoma mansoni","volume":"27","author":"Carvalho","year":"1985","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0760","first-page":"39","article-title":"Esquistossomose mans\u00f4nica: diagn\u00f3stico, tratamento, epidemiologia, profilaxia e controle","volume":"10","author":"Vitorino","year":"2012","journal-title":"Rev Bras Clin Med S\u00e3o Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0765","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1590\/S0037-86821973000600008","article-title":"Estudo de uma cepa humana de Schistosoma mansoni resistente a agentes esquistossomicidas","volume":"7","author":"Katz","year":"1973","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.bmc.2017.04.031_b0770","first-page":"48","article-title":"Resist\u00eancia ao hycanthone e oxamniquine em doentes com esquistossomose com a forma cl\u00ednica hepatointestinal","volume":"25","author":"Guimar\u00e3es","year":"1979","journal-title":"Rev Assoc M\u00e9dica Bras"},{"key":"10.1016\/j.bmc.2017.04.031_b0775","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1590\/S0034-89101978000100013","article-title":"Linhagem humana de Schistosoma mansoni resistente a esquistossomicidas","volume":"12","author":"Dias","year":"1978","journal-title":"Rev Sa\u00fade P\u00fablica"},{"key":"10.1016\/j.bmc.2017.04.031_b0780","first-page":"32","article-title":"Observations of the treatment of mansoni schistosomiasis with oxamniquine: efficacy in children and in persistent salmonellosis; resistance of a strain of Schistosoma mansoni; hepatic toxicity and neurological side effects","volume":"22","author":"Pedro","year":"1980","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0785","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4269\/ajtmh.1980.29.890","article-title":"Susceptibility to chemotherapeutic agents of strains of Schistosoma mansoni isolated from treated and untreated patients","volume":"29","author":"Araujo","year":"1980","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0790","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0035-9203(82)90235-8","article-title":"Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and\/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents","volume":"76","author":"Souza Dias","year":"1982","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0795","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0035-9203(87)90032-0","article-title":"Tolerance of Kenyan Schistosoma mansoni to oxamniquine","volume":"81","author":"Coles","year":"1987","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0800","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/S0036-46651988000200005","article-title":"Variation in response of Schistosoma mansoni strains to schistosomicides","volume":"30","author":"Dias","year":"1988","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"10.1016\/j.bmc.2017.04.031_b0805","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1590\/S0074-02761993000100014","article-title":"Response of drug resistant isolates of Schistosoma mansoni to antischistosomal agents","volume":"88","author":"Drescher","year":"1993","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmc.2017.04.031_b0810","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4269\/ajtmh.1994.51.83","article-title":"Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific","volume":"51","author":"Fallon","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2017.04.031_b0815","doi-asserted-by":"crossref","unstructured":"Coelho PMZ, Lim E Silva FC, Nogueira-Machado JA. Resistance to oxamniquine of a Schistosoma mansoni strain isolated from patient submitted to repeated treatments, Rev Inst Med Trop S\u00e3o Paulo, 1997, 39, 101\u2013106.","DOI":"10.1590\/S0036-46651997000200007"},{"key":"10.1016\/j.bmc.2017.04.031_b0820","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1590\/S0074-02762000000300013","article-title":"Study of Schistosoma mansoni isolates from patients with failure of treatment with oxamniquine","volume":"95","author":"Concei\u00e7\u00e3o","year":"2000","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmc.2017.04.031_b0825","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1590\/S0074-02762002000300019","article-title":"Altered response of strain of Schistosoma mansoni to oxamniquine and praziquantel","volume":"97","author":"Bonesso-Sabadini","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmc.2017.04.031_b0830","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1590\/S0074-02761987000800026","article-title":"The significance of variation in the susceptibility of Schistosoma mansoni to the antischistosomal drug oxamniquine","volume":"82","author":"Kinoti","year":"1987","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmc.2017.04.031_b0835","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/expr.1993.1104","article-title":"Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone\/oxamniquine-resistant strains are mutated in the same gene","volume":"77","author":"Picamattoccia","year":"1993","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.bmc.2017.04.031_b0840","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0169-4758(93)90138-6","article-title":"Drug resistance in schistosomes","volume":"9","author":"Cioli","year":"1993","journal-title":"Parasitol Today"},{"key":"10.1016\/j.bmc.2017.04.031_b0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004132","article-title":"Structural and functional characterization of the enantiomers of the antischistosomal drug oxamniquine","volume":"9","author":"Taylor","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2017.04.031_b0850","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1590\/S1516-93322008000400022","article-title":"S\u00edntese e atividade biol\u00f3gica do derivado 6-formil-oxamniquina","volume":"44","author":"de Almeida","year":"2008","journal-title":"Rev Bras Ci\u00eanc Farm"},{"key":"10.1016\/j.bmc.2017.04.031_b0855","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0079-6700(94)00031-V","article-title":"Macromolecular prodrugs","volume":"20","author":"Ouchi","year":"1995","journal-title":"Prog Polym Sci"},{"key":"10.1016\/j.bmc.2017.04.031_b0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/apmc.1997.052450101","article-title":"Polymeric prodrugs. Synthesis, release study and antimicrobial properties of polymer-bound acriflavine","volume":"245","author":"Patel","year":"1997","journal-title":"Angew Makromol Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(01)00257-7","article-title":"Modulated release of cyclosporine from soluble vinyl pyrrolidone\u2013hydroxyethyl methacrylate copolymer hydrogels: a correlation of \u201cin vitro\u201d and \u201cin vivo\u201d experiments","volume":"72","author":"Gallardo","year":"2001","journal-title":"J Controlled Release"},{"key":"10.1016\/j.bmc.2017.04.031_b0870","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0142-9612(00)00176-9","article-title":"Synthesis, characterization and in vitro degradation of a new family of alternate poly(ester-anhydrides) based on aliphatic and aromatic diacids","volume":"22","author":"Jiang","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmc.2017.04.031_b0875","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0168-3659(96)01614-8","article-title":"Acrylic type polymers containing ibuprofen and indomethacin with difunctional spacer group: synthesis and hydrolysis","volume":"47","author":"Davaran","year":"1997","journal-title":"J Controlled Release"},{"key":"10.1016\/j.bmc.2017.04.031_b0880","series-title":"The Practice of Medicinal Chemistry","author":"Wermuth","year":"2015"},{"key":"10.1016\/j.bmc.2017.04.031_b0885","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bmc.2006.11.027","article-title":"Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs","volume":"15","author":"Filho","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2017.04.031_b0890","unstructured":"Ferrari MLA, Coelho PMZ, Antunes CMF, Tavares CAP, Cunha AS da. Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2572425\/. Accessed September 22, 2016."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617302213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617302213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:50:29Z","timestamp":1760835029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089617302213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":178,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0968089617302213"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2017.04.031","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2017.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}